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Abstract 
Background: Pegylated‑interferon alpha (PegINFα) treatment of patients with polycythemia vera (PV) and essential 
thrombocythemia (ET) has resulted in long‑term clinical response, decreased JAK2V617F allelic burden and restoration 
of polyclonal hematopoiesis. The mechanisms of the beneficial effects of PegINFα are not clear, but available evidence 
suggests direct suppression of JAK2‑mutated clone, induction of dormant stem cells to proliferation, and augmenta‑
tion of an immune effect against PV and ET clones.
Methods: We analyzed the phenotype and frequency of peripheral blood lymphocytes (PBL) from PegINFα treated 
patients and compared them to patients treated with hydroxyurea (HU). Samples collected at various time points 
before and during treatment were analyzed using multicolor flow cytometry.
Results: We found that PegINFα increased the frequency of peripheral blood CD4+ Foxp3+ regulatory T cells (Treg). 
Highly suppressive Treg, characterized by co‑expression of CD39 and HLA‑DR, were also increased in PBL from 
PegINFα treated patients. We observed an augmentation of cycling CD8+ T cells, NK cells, and of poorly activated 
CD38+CD8+ T cells. Our results also suggest that PegINFα increased the frequency of PD‑1+ CD4+ helper cells and 
PD‑1+ CD4+ Foxp3+ Treg cells. None of these changes were present in HU treated patients. We analyzed the cor‑
relation between changes in different T cell populations in the peripheral blood with the changes in JAK2V617F allelic 
burden in clonal granulocytes. Augmentation of Ki‑67+ Treg, HLA‑DR+ CD39+ Treg, Helios+ Treg and HLA‑DR+ CD38+ 
CD8+ T cells correlated with an increase in JAK2V617F allelic burden. We also found a positive correlation between 
PD‑1+ Treg and JAK2V617F allelic burden; however, the number of available patients was small (n = 7).
Conclusions: We report marked changes in frequencies of PBL subsets after PegINFα treatment, suggesting an 
immunomodulatory effect by PegINFα. Generation of a more suppressive immune response, as measured by an 
increase in highly suppressive Treg and poorly activated CD8+ T cells, correlated with a poor molecular response. In 
this study, we have not identified changes in the PBL that would indicate the presence of an effective anti‑tumor 
response. 
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Background
Polycythemia vera (PV) and essential thrombocytosis (ET) 
are myeloproliferative neoplasms (MPN) characterized by 
the excessive proliferation but unhindered differentiation 
of a hematopoietic stem cell clone. The JAK2V617F muta-
tion is present in more than 95 % of patients with PV and 
more than 50 % of patients with ET [1–4]. Chemotherapy 
decreases cell counts and thrombotic events by suppress-
ing proliferation of PV and ET clones, but only interferon 
alpha (INFα) has occasionally restored polyclonal hemat-
opoiesis [5] and often reduced JAK2V617F allelic burden 
[6]. However, there are multiple mechanisms by which 
INFα promotes this response, including a direct suppres-
sion of JAK2 mutated hematopoietic progenitors [7, 8], 
stimulation of quiescent residual normal cells by promot-
ing cell division, differentiation of hematopoietic stem and 
progenitor cells [9], or beneficial alteration of humoral 
and cellular immune responses.
The role of T cells in tumor immunity is well established. 
The recent successes of immunomodulatory therapies such 
as antibodies targeting checkpoint molecules or adaptive 
T cell therapy have clearly established the role of immu-
notherapy in the treatment of a variety of cancers, such as 
melanoma, renal carcinoma and non-small lung cancer [10, 
11]. It was previously reported that INFα increases func-
tion of CD4 effector T-cells, CD8+ T-cells and B-cells and 
that it may exert anti-tumor effects. [12–14]. INFα effects 
on Treg are not fully understood. However, some studies 
have shown an activating effect of INFα on Treg [15, 16]. 
Thus, in melanoma patients, INFα treatment is used as an 
adjuvant therapy [17] and the systemic immune effects of 
INFα in these patients have been described [18].
Failure of the immune system to control clonal growth 
is very often due to immunological imbalance. In many 
cancers, Treg are increased and contribute to the failure 
of the immune system to clear the tumor. Several types 
of Treg with distinct functional differences have been 
recognized. Treg that co-express CD39 and HLA-DR are 
more suppressive than Treg that do not express these two 
surface markers [19]. Another highly suppressive Treg 
subset is characterized by expression of the Ikaros family 
member transcription factor Helios [20]. A decrease in 
a highly suppressive CD39+ and HLA-DR+ Treg subset 
has been correlated with a decreased tolerance, resulting 
in kidney graft rejection or pre-term pregnancy loss [21, 
22]. Increased Helios+ Treg have been observed in tumor 
infiltrating lymphocytes [23].
To be fully functional, CD8+ T cells need to be stim-
ulated along a well-defined pathway [24]. First, a T cell 
receptor is engaged by its cognate MHC-peptide com-
plex. Then a second signal is delivered when CD28 
expressed at the surface of activated T cells is engaged 
by B7 present at the surface of antigen presenting cells. 
To fully activate T cells, a third signal is necessary and is 
provided by the engagement of OX40 by its ligand OX40 
ligand. OX40 is a member of the tumor necrosis super-
family expressed at the surface of recently activated T 
cells [25]. Failure to accomplish these three steps leads 
to poorly activated, hypofunctional T cells characterized 
by co-expression of CD38 and HLA-DR. Non-specific 
activation, or bystander activation, is often observed in 
cancer or acquired immunodeficiency syndrome [26]. In 
patients infected with human immunodeficiency virus, 
the presence of CD38+ HLA-DR+ CD8+ T cells corre-
lates with early progression of disease [27].
To prevent overactivation of the immune system, sev-
eral checkpoint molecules control T cell activation and 
prevent accumulation of activated T cells. CTLA-4, a 
member of the immunoglobulin superfamily, upon bind-
ing of its ligand (CD80 or CD86), inhibits proliferation of 
effector T cells. PD-1, a member of the CD28 family, is 
expressed on T cells upon activation, and its engagement 
by PDL-1 or PDL-2, results in T cell death, anergy and 
exhaustion. High levels of CTLA-4 or PD-1 expression 
on tumor infiltrating T cells contributes to dysregulation 
of the immune response in cancer patients.
In this study, we attempted to determine whether 
PegINFα stimulation of the immune system contributes 
to the beneficial response to PegINFα therapy. PegINFα 
is a form of INFα with a longer half-life, less toxicity and 
more convenient administration. Riley and colleagues 
have reported an increase in circulating NK cells and Treg 
in MPN patients treated with PegINFα [28–30]; however, 
no correlation with clinical, cytological, or molecular 
response to therapy was reported. This study confirms 
increased circulating NK cells and Treg after PegINFα 
therapy and provides a more detailed characterization 
of PBL in patients treated with PegINFα. We report a 
positive correlation between changes in JAK2V617F allelic 
burden and changes in lymphocyte populations in the 
Trial registration NCT01259856, December 7. 2010 and NCT01259817, December 6. 2010, Grant #1P01CA108671‑O1A2, 
July 17. 2006, Sponsor: MPDRC/NIH, NCI‑2012‑00269, January 12. 2011 and NCI‑2012‑00268, January 12. 2011
Keywords: Myeloproliferative neoplasms, Pegylated‑interferon alpha, Regulatory T cells, Immune monitoring, 
Immune checkpoint, JAK2V617F
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peripheral blood. These changes are independent of 
myelosuppression, as they were not observed in PV and 
ET patients treated with HU. We hypothesize that the 
increase in CD39+ HLA-DR+ Treg contributes to sup-
pression of the immune response, resulting in treatment 
failure. We suggest that increased CD39+ HLA-DR+ Treg 
could be used as a biomarker to predict if Peginfα treat-
ment will have beneficial effects in MPN patients.
Methods
Study subjects
This study included the following three groups of sub-
jects: (1) patients who participated in MPD-RC 112, a 
Phase 3 randomized trial in high-risk PV and ET using 
PegINFα versus HU; (2) patients who participated in 
MPD-RC 111 for PV and ET patients intolerant or 
refractory to hydroxyurea and patients with Budd Chi-
ari syndrome (both trials are part of the Myeloprolifera-
tive Disorders Research Consortium); and (3) patients 
who did not participate in these protocols. Peripheral 
blood samples were collected prior to and at different 
time points during treatment, after patients signed an 
approved Institutional Review Board informed consent. 
Patient’s characteristics are described in Table 1.
Trial registration
NCT01259856, December 7. 2010, NCT01259817, 
December 6. 2010, IRB_00017793, grant #1P01CA108671- 
O1A2, July 17. 2006, Sponsor: MPDRC/NIH, IRB_ 45342, 
NCI-2012-00269, January 12. 2011 and IRB_36791, NCI-
2012-00268, January 12. 2011.
Blood sample processing
10  mL of peripheral blood were obtained by venipunc-
ture. Granulocyte and mononuclear cell fractions were 
isolated according to previously published protocols [31, 
32]. After isolation, PBMC were frozen and stored prior 
to analysis.
Flow cytometry
Single cell suspensions of leukocytes from peripheral 
blood were stained using the following monoclonal 
antibodies: anti-CD3 APC-H7 (BD, 641397), anti-CD4 
Alexa Fluor 700 (BD, 557922), anti-CD8 Alexa Fluor 
700 (BD, 557945), anti-CD25 APC (Miltenyi 130-
092-858), anti-CD28 BV421(BD, 562613), anti-CD38 
BV605 (Biolegend 303532), anti-HLA-DR PE-Cy7 (BD 
Biosciences, 335795), anti-CD39 BV421 (BD 563679), 
anti-CD45 RO BV510 (BD, 563215), anti-CD56 APC 
(Biolegend 318310), anti-CCR7 PE (BD 561008), anti-
FoxP3 PE (eBioscience, 12-4777-42), anti-Ki-67 FITC 
(BD 556026), anti-HELIOS (Biolegend, 137214), anti-
CTLA-4 APC (BD 560938), anti-OX40 FITC (Bioleg-
end 35006), and anti-PD1 BV510 (Biolegend 329932). 
Cells were stained in FACs buffer (1 % FBS in PBS with 
0.01  % NaN3) and fixed according to the eBioscience 
FoxP3 Fix-Perm kit protocol (eBioscience, 00-5521-00). 
All samples were analyzed on a BD X20 Fortessa Flow 
cytometer. We used Fluorescence Minus One to dis-
criminate between positive and negative cells for each 
antibody [33].
DNA isolation and JAK2V617F analysis
Genomic DNA was isolated from granulocytes using 
Puregene DNA purification kits (Gentra, MN, USA). 
The JAK2V617F mutational burden was determined by 
quantitative real-time allele specific PCR (qRT-PCR) 
employing a sequence 7500 detection system (Applied 
Biosystems, Foster City CA, USA) in which an allele-spe-
cific primers, containing both a mismatched nucleotide 
and a locked nucleic acid, are used to enhance discrimi-
nation between polymorphic nucleotides, as previously 
described [34].
PBL and JAK2V617F correlation analysis
Correlation matrices were created to identify poten-
tial bivariate linear relationships between changes 
in peripheral blood Treg populations and changes in 
JAK2V617 allelic burden. Significantly correlated vari-
ables, with corresponding Pearson’s product-moment 
correlation coefficient (r) and p value, are presented 
in Fig.  6. A generalized linear model (GLM) was cal-
culated for each pair as well. However, for interpreta-
tion, r was preferable to the beta coefficients to include 
in Fig.  6. Analysis was performed adapting the cor.test 
and corrplot functions using R software version 3.2.3 
(Copyright (C) 2015 The R Foundation for Statistical 
Computing).
Table 1 Patient’s characteristic
PegIFNα (n = 25) Hydroxyurea (n = 7)
Age 57.0 64





JAK2V617F allelic burden 25.4 60
Median (range) (1.0–99.2) (4.54–93.3)
Hematocrit  % 46.9 50.5
Median (range) (28.7–70) (33.4–70.2)
WBC ×109/L 8.1 8.0
Median (range) (2.5–17.3) (4.3–12.5)
Platelets × 109/L 391 393
Median (range) (112–1555) (123–878)
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Results
PegINFα increases the frequency of CD4+ Foxp3+ Treg 
and highly suppressive Treg in peripheral blood
Under the approval of our institute’s Institutional Review 
Board, 32 patients with MPN were enrolled in the study. 
As described in Table  1, 25 patients were treated with 
PegINFα and 7 with HU.
Peripheral blood samples were received and processed 
as described in “Methods” section. To determine the 
effects of PegINFα on peripheral blood Treg, we per-
formed multicolor flow cytometry analysis with anti-
bodies that recognize CD3, CD4, CD25, Foxp3, CD39, 
HLA-DR, Helios and Ki-67. Changes in T-cell subpopu-
lations were analyzed by prism using fluorescence minus 
one as internal controls. Peripheral blood mononuclear 
cells (PBMC) were gated on CD3 and CD4 and then fur-
ther analyzed for Ki-67, a marker of cell proliferation, as 
well as Foxp3 and CD25, markers of Treg. Treg were fur-
ther analyzed for co-expression of CD39 and HLA-DR, 
and expression of Helios. Treg expressing these mark-
ers represent Treg that are more suppressive. An exam-
ple of flow cytometry analysis is shown in Additional 
file  1: Fig.  S1. As shown in Fig.  1a, CD4+ Foxp3+ Treg 
increased from 6.4 to 9.9  %, p  =  0.0017, in patients 
receiving PegINFα, while no change was observed in 
HU treated patients. This increase continued with time 
and was higher after 52  weeks of treatment at 11.4  % 
(Fig. 1b).
For 18 of 25 patients treated with PegINFα and 5 of 7 
HU treated patients, we were able to perform a more 
detailed analysis of the Treg population. The prolifera-
tion of Treg as measured by Ki-67 was not significantly 
increased in PegINFα treated patients (12.3–14.4  % 
p = 0.5509) (Fig. 1c). When analyzing the more suppres-
sive phenotype of Treg, we observed that PegINFα signifi-
cantly increased the proportion of CD39+ HLA-DR+ Treg 
from 10.6 to 16.7 %, p = 0.0139 (Fig. 1d). No significant 
increase in the proportion of Helios+ Treg (63.15–64.2 % 
p  =  0.2188) was observed in PegINFα treated patients 
(Fig.  1e). There was no statistically significant change 
in the absolute number of CD39+ HLA-DR+, Ki-67+ or 
Helios+ Treg in Peginfa treated patients (Additional file 2: 
Fig.  S2). We did not observe any significant changes in 














































































































































































































Fig. 1 PegINFα increases Treg and highly suppressive Treg cells in peripheral blood of PV and ET patients. PBMC were collected from patients with 
PV or ET treated with PegINFα or HU for at least 70 days (range 70–616, median 112 for PegINFα and range 113–2422, median 175 for HU treated 
patients). Lymphocytes were analyzed by flow cytometry using surface markers, CD3, CD4, CD25, CD39, HLA‑DR and intracellular markers Foxp3, 
Ki‑67 and Helios. a represents CD4+ CD25+ Foxp3+ Treg cells. In b the frequency of Treg was analyzed at different time points after initiation of 
PegINFα treatment. c–e show frequency of Ki‑67+ Treg, Helios+ Treg, and CD39+/HLA‑DR+) Treg
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Proliferation and phenotypic changes in CD8+ T cells 
induced by PegINFα
Next, we analyzed CD8+ CD3+ cytotoxic T cells for 
expression of CD28, Ki-67, CD38 and HLA-DR before 
and after therapy with PegINFα or HU. The frequency 
of CD8+ T cells was not affected by PegINFα (20.3 and 
20.1  %) or HU (21.8 and 13.8  %), respectively (Fig.  2a). 
However, in PegINFα treated patients, a higher pro-
portion of CD8+ T cells co-expressed Ki-67, indicating 
increased proliferation (4.6–7.5  %, p  =  0.001). HU did 
not induce proliferation of CD8+ T cells (Fig. 2b). Moreo-
ver, we observed phenotypic differences in CD8+ T cells, 
including a significant increase in the CD38+ HLA-DR+ 
CD8+ subset, representing activated cells, in patients 
receiving PegINFα (10.2  % before treatment and 21.2  % 
during treatment, p = 0.0015; Fig. 2c). No changes were 
observed in HU treated patients.
PegINFα induces expression of checkpoint molecules on T 
cells
We investigated the expression of checkpoint mole-
cules PD-1 and CTLA-4 on CD3+ T cells in peripheral 
blood in 14 of 25 PegINFα treated patients and 4 of 7 
HU treated patients. The frequency of peripheral blood 
CD4+ Treg and CD4+ effector T cells (Teff) express-
ing PD-1 increased in PegINFα-treated patients (0.18  % 
before treatment and 0.44  % during treatment for Treg, 
p =  0.016; and 1.2–3.1  % Teff, p =  0.0029) (Fig.  3c, d). 
The proportion of CTLA-4 expressing Treg was also aug-
mented in patients treated with PegINFα (Fig. 3a, b). HU 
did not affect the expression of either PD-1 or CTLA-4.
Increased CD3− CD56+ NK cell proliferation
Analysis of CD3− CD56+ NK cells was performed in 9 of 
25 patients receiving PegINFα and 3 of 7 patients treated 
with HU. PegINFα did not affect the proportion of NK 
cells in the peripheral blood. However, the proportion of 
dividing NK cells was significantly increased, as shown 
in Fig.  4a, b. Prior to PegINFα treatment, 7.8  % of NK 
cells were proliferating; after at least 10  weeks of treat-
ment, the frequency increased to 17.3 %, p = 0.0078. No 
changes were observed in HU treated patients.
Correlation between peripheral blood T cells 
and molecular response in PegINFα treated patients
In 18 PV and 7 ET patients treated with PegINFα, molec-
ular response was evaluated by measuring the JAK2V617F 
allelic burden. One ET patient was JAK2V617F negative and 
carried a calreticulin mutation and another ET patient 
was triple negative [35]. Patients were subdivided into 
two groups based on percentage reduction of JAK2V617F 
allelic burden. Patients with a 20 % or greater decrease in 
JAK2V617F allelic burden were categorized as responders 
(R), and those with a less than 20 % decrease were catego-
rized as non-responders (NR). In this cohort, there were 
10 R (9 PV and 1 ET) and 13 NR (9 PV and 4 ET).
We sought to determine whether changes in PBL cor-
related with changes in JAK2V617F allelic burden. As 
shown in Fig.  5, we observed several trends consistent 
with previously published data in other malignancies. NR 
showed a higher increase of Treg frequency, Treg prolif-
eration and highly suppressive CD39+ HLA-DR+ Treg 
frequency. When looking at changes in absolute Treg, a 
similar trend was observed (Additional file 3: Fig. S3). A 
more pronounced increase of CD38+ HLA-DR+ CD8+ T 
cells were observed in NR.
Changes in PBL correlate with JAK2V617F allelic burden
Using Spearman correlation analysis, we identified 
several Treg populations that increased in the periph-
eral blood and correlated with an increase in JAK2V617F 
allelic burden. An increased proportion of Ki-67+ Treg, 
HLA-DR+ CD39+ Treg and Helios+ Treg correlated 
with an increase in JAK2V617F allelic burden (Fig. 6a–c). 
Analysis of seven patients shows a strong positive cor-





















































































































Fig. 2 Increased proliferation and activation of CD8+ T cells in peripheral blood of PegINFα treated patients. PBMC collected prior to and after at 
least 10 weeks of treatment were analyzed using anti‑CD3, ‑CD8, ‑CD38, ‑HLA‑DR and Ki‑67 antibodies. Percentage of CD8+ T cells, cycling (Ki‑67+) 
CD8+ T cells and CD38+/HLA‑DR+ CD8+ T cells are shown in (a–c) respectively
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burden (Fig.  6d). These data need to be confirmed in a 
larger number of patients. We observed that an increase 
in the CD38+ HLA-DR+ CD8+ T cell subset also cor-
related with an increases in the JAK2V617F allelic burden 
(Fig. 6e).
Discussion
PegINFα is the only treatment for PV and ET patients 
reported to result in long-term clinical and molecu-
lar remission [34]. In some patients, we observed 
a marked decrease of JAK2V617F allelic burden that 
persisted even after discontinuation of treatment, 
suggesting a PegINFα-induced immune-mediated 
mechanism. INFα increases tumor immunogenicity, 
activates antigen presenting cells, and stimulates both 
CD4+ and CD8+ T cells [36, 37]. Several other stud-
ies analyzed PBL, characterized the effect of PegINFα 
and reported similar results [28, 29]. Previously, our 
group also reported an increase of Treg in PV and ET 
patients during therapy with PegINFα [38]. However, a 
detailed analysis of PBL subsets and their correlation 
with clinical and molecular response had not previ-
ously been established.
In this study, we used multi-color flow cytometry to 
analyze PBL of PV and ET patients treated with PegINFα 
or HU. We found an increase in peripheral blood Treg in 
patients treated with PegINFα. In addition, the frequency 
of highly suppressive CD39+ HLA-DR+ Treg was also 
increased. In the NR subset of patients, we found a trend 
towards increased frequency of Treg, increased prolifera-
tion of Treg and increased CD39+ HLA-DR+ Treg com-
pared to the R group (p = 0.55, p = 0.2530, p = 0.4078 
respectively). When looking at the absolute numbers of 
Treg, no significant changes were observed. However, 
since PegINFα decreased absolute lymphocyte counts, 
it was interesting to observe that CD39+ HLA-DR+ Treg 



























































































































































Fig. 3 Expression of checkpoint molecules is increased by PegINFα. 
CD3+ CD4+T cells in peripheral blood were separated into Treg and 
non‑Treg based on the expression of Foxp3. Foxp3+ Treg, (a and c) or 
Foxp3− non‑Treg (b and d) were examined for expression of CTLA‑4 


















































































Fig. 4 Increased CD3−/CD56+ NK cells proliferation in peripheral 
blood of PV and ET patients treated with PegINFα. PBMC were col‑
lected from patients prior to and after at least 10 weeks of treatment 
and analyzed for surface markers CD3 and CD56 and intra‑cellular 
marker Ki‑67. a shows CD56+ frequency and b shows frequency of 































































































































Fig. 5 Changes in T cell subsets vary based on molecular response. 
Patients treated with PegINFα were separated into R and NR subsets 
based on a 20 % decrease in JAK2V617 allelic burden. PBMC were 
analyzed as described above and fold changes compare to baseline 
were examined. a represents 23 patient samples (10R and 13 NR), b, c 
include 16 patients (6R and 10NR), and d includes 13 patients (4R and 
9 NR). a–c show frequency of Treg, dividing Treg, CD39+ HLA‑DR+ 
Treg and Helios+ Treg. d shows CD38+ HLA‑DR+ T cells in R vs NR
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We assessed if changes in PBL subpopulations pre-
dicted molecular response. We found a positive cor-
relation between increased proliferating Treg (Ki-67+ 
Treg), highly suppressive Treg (HLA-DR+/CD39+ or 
Helios+ Treg) and JAK2V617F allelic burden. We also 
found a positive correlation between increased HLA-
DR+ CD38+ CD8+ T cells and increased JAK2V617F 
allelic burden. Similar results were observed in hepa-
titis C patients treated with INFα. Su et  al. reported 
that patients presenting with virological response 
had lower circulating Treg [39]. Although periph-
eral blood changes may not necessarily reflect the 
marrow microenvironment [40], the easy accessibil-
ity of peripheral blood permits convenient monitor-
ing of patients undergoing PegINFα therapy. Our 
data indicate that Treg play an important role in the 
pathophysiology of PV and ET and that failure of 
PegINFα to decrease circulating Treg predicts a poor 
molecular response.
Conclusion
These results suggest that activation of the immune sys-
tem by PegINFα can induce either a protective immune 
response that contributes to elimination of the malig-
nant clone or a suppressive immune response, suggesting 
that increases in Treg prevent clearance of the mutated 
clone by effector CD8+ T cells. Further studies analyzing 
changes in immune cells in bone marrow may elucidate 
the role of PegINFα in inducing anti-tumor responses. 
We found that changes in peripheral blood T cell popula-
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Fig. 6 Correlation between increasing JAK2 V617 allelic burden in patients treated with PegINFα and augmentation of peripheral blood Treg popula‑
tions. Changes in peripheral blood Treg population were correlated with changes in JAK2 V617 allelic burden. a Ki‑67+ Treg, CD39+/HLA‑DR+ Treg (b), 
Helios+ Treg (c), PD‑1+ Treg (d) and CD38+ HLA‑DR+ CD8+ T cells (e)
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sive Treg in peripheral blood of PV and ET patients are not significantly 
affected by Peginfα. PBMC were collected from patients with PV or ET 
treated with PegINFα or HU for at least 70 days (range 70‑616 days, 
median 112 days, for PegINFα and range 113‑2422 days, median 175 days, 
for HU treated patients). Lymphocytes were analyzed by flow cytometry 
using surface markers CD3, CD4, CD25, CD39, HLA‑DR and intracellular 
markers Foxp3, Ki‑67 and Helios. Panel A represents absolute numbers of 
CD4+ CD25+ Foxp3+ Treg cells. In panel B, the absolute number of Treg 
was analyzed at different time points after initiation of PegINFα treatment. 
Panels C‑D‑E show the absolute number of Ki‑67+ Treg, Helios+ Treg, and 
CD39+/HLA‑DR+ Treg.
Additional file 3: FigS3. Changes in numbers of Treg subsets in Peginfa 
treated patients based on molecular response. Patients treated with 
PegINFα were separated into R and NR subsets based on a 20% decrease 
in JAK2V617 allelic burden. PBMC were analyzed as described above and 
fold changes compare to baseline were examined. Panel A represents 
23 patient samples (10R and 13NR), panels B‑C include 16 patients (6 R 
and 10 NR), and panel D includes 13 patients (4R and 9NR). A‑C show the 
number of Treg, of dividing Treg, of CD39+ HLA‑DR+ Treg and Helios+ 
Treg. Panel D shows CD38+ HLA‑DR+ T cells in R vs NR.
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